Members |
targetComponentId |
Cortex contusion without mention of intracranial wound, with 1-24 hours loss of consciousness |
Contusion of cerebral cortex |
Cortex contusion without mention of open intracranial wound, with less than 1 hour loss of consciousness |
Contusion of cerebral cortex |
Cortex contusion without mention of open intracranial wound, with loss of consciousness of unspecified duration |
Contusion of cerebral cortex |
Cortex contusion without mention of open intracranial wound, with more than 24 hours loss of consciousness and return to pre-existing conscious level |
Contusion of cerebral cortex |
Cortex contusion without mention of open intracranial wound, with more than 24 hours loss of consciousness without return to pre-existing conscious level |
Contusion of cerebral cortex |
Cortex contusion without mention of open intracranial wound, with no loss of consciousness |
Contusion of cerebral cortex |
Cortex contusion without mention of open intracranial wound, with unspecified state of consciousness |
Contusion of cerebral cortex |
Cortex contusion without open intracranial wound |
Contusion of cerebral cortex |
Cortex contusion without open intracranial wound AND with concussion |
Contusion of cerebral cortex |
Cortex contusion without open intracranial wound AND with loss of consciousness |
Contusion of cerebral cortex |
Cortex contusion without open intracranial wound and with unspecified state of consciousness |
Contusion of cerebral cortex |
Cortex laceration with open intracranial wound and unspecified state of consciousness |
Cortex laceration with open intracranial wound |
Cortical dysplasia with focal epilepsy syndrome |
CNTNAP2-related developmental and epileptic encephalopathy |
Corticosteroid binding globulin |
Corticotropin binding globulin |
Corynebacterium flaccumfaciens |
Curtobacterium flaccumfaciens (organism) |
Corynebacterium flaccumfaciens subsp betae |
Curtobacterium flaccumfaciens (organism) |
Corynebacterium flaccumfaciens subsp oortii |
Curtobacterium flaccumfaciens (organism) |
Corynebacterium flaccumfaciens subsp poinsettiae |
Curtobacterium flaccumfaciens (organism) |
Corynebacterium liquefaciens |
Brevibacterium liquefaciens |
Corynebacterium nigricans |
Corynebacterium aurimucosum (organism) |
Corynebacterium paurometabolum |
Tsukamurella paurometabola (organism) |
Corynebacterium vitarumen |
Corynebacterium vitaeruminis (organism) |
Count of active ingredient |
Count of active ingredient (attribute) |
Count of base and modification pair |
Count of base and modification pair (attribute) |
Count of base of active ingredient |
Count of base of active ingredient |
Count of clinical drug type |
Count of clinical drug type (attribute) |
Counter irritants adverse reaction |
Adverse reaction to drug |
Course |
Clinical course |
Cowdria |
Ehrlichia |
Cowdria ruminantium |
Ehrlichia ruminantium (organism) |
Coxarthrolisthetic pelvis |
Coxitis (disorder) |
Crab - dietary |
Crab (substance) |
Cranial manipulation |
Osteopathic cranial manipulative medicine (procedure) |
Craniectomy, trephination, bone flap craniotomy for coagulation of choroid plexus |
Craniectomy |
Craniectomy, trephination, bone flap craniotomy for total hemispherectomy |
Spinal cordotomy |
Craniofenestria |
Craniolacunia |
Craniomandibular osteopathy |
Hyperostosis of skull (finding) |
Craniosacral manipulation |
Osteopathic cranial manipulative medicine (procedure) |
Craniosynostosis with facial dysmorphism and brachydactyly syndrome |
Fibroblast growth factor receptor 3-related craniosynostosis (disorder) |
Crax mitu |
Mitu mitu (organism) |
Crayfish - dietary |
Crayfish (substance) |
Creation ileostomy: [OS] or [Gross] |
Creation of ileostomy |
Creation of Gross ileostomy |
Creation of ileostomy |
Creation of arterioarterial bypass |
Arterial bypass graft |
Creation of lesion of spinal cord by any modality |
Spinal cord destructive procedure |
Creation of oleothorax |
Procedure on thorax |
Crimean fever |
Congo-Crimean hemorrhagic fever (disorder) |
Cromoglycate and related antiallergenic allergy |
Allergy to cromoglicic acid (finding) |
Cromolyn sodium 0.8mg/spray |
Sodium cromoglicate 800 microgram/actuation powder for inhalation |
Cromolyn sodium 8.1g spray |
Sodium cromoglicate 800 microgram/actuation powder for inhalation |
Cross-linked hyaluronic acid 24mg/mL injection gel |
Hyaluronic acid only product in parenteral dose form |
Crown heel length |
Recumbent body height (observable entity) |
Crown, full cast high noble metal |
Restoration of tooth with full coverage noble metal crown (procedure) |
Crown, full cast noble metal |
Restoration of tooth with full coverage noble metal crown (procedure) |
Crown, porcelain fused to high noble metal |
Restoration of tooth using porcelain fused to noble metal crown |
Crown, porcelain fused to noble metal |
Restoration of tooth using porcelain fused to noble metal crown |
Crown, resin with high noble metal |
Restoration of tooth with resin and noble metal crown (procedure) |
Crown, resin with noble metal |
Restoration of tooth with resin and noble metal crown (procedure) |
Cruelty |
Cruel behavior |
Crushing injury of multiple sites of shoulder AND/OR upper arm (disorder) |
Crushing injury of multiple sites of upper limb |
Crushing injury of multiple sites, NEC |
Crushing injury of multiple sites |
Crustacean |
Subphylum Crustacea (organism) |
Crutches |
Crutch |
Cryotherapy to lesion of organ NOC |
Cryotherapy |
Cryotherapy to organ NOC |
Cryotherapy |
Cryotherapy to organ NOC NOS |
Cryotherapy |
Cryotherapy to organ NOC OS |
Cryotherapy |
Cryptococcus albidus variant albidus |
Naganishia albida (organism) |
Cryptococcus antigen level |
Cryptococcus species antigen assay |
Cryptococcus antigen level |
Cryptococcus species antigen assay |
Cryptococcus antigen level |
Cryptococcus species antigen assay |
Cryptococcus neoformans var gattii |
Cryptococcus gattii (organism) |
Cryptogenic |
Unknown (origin) |
Cryptogenic generalized epilepsy |
Generalized epilepsy |
Cryptogenic myoclonic epilepsy |
Generalized epilepsy |
Crystal arthropathy of other site |
Crystal arthropathy |
Crystal violet tattoo |
Crystal violet tattoo |
Cucumber - dietary |
Cucumber (substance) |
Cucumovirus group |
Genus Cucumovirus (organism) |
Curettage of lesion of organ NOC |
Curettage |
Curettage of organ NOC |
Curettage |
Curettage of organ NOC NOS |
Curettage |
Curettage of organ NOC OS |
Curettage |
Curettage of products of conception from uterus NEC |
Dilation of cervix uteri and curettage of products of conception from uterus |
Curettage products conception: [uterus NEC (& retained)] or [termination NEC] |
Dilation of cervix uteri and curettage of products of conception from uterus |
Curling esophagus |
Diffuse spasm of esophagus |
Curvature of stomach |
Stomach part |
Cutaneous CD30+ lymphoproliferative disorder |
Primary cutaneous CD30+ large T-cell lymphoma |
Cutaneous T-cell lymphoma, no International Classification of Diseases for Oncology subtype |
Cutaneous T-cell lymphoma |
Cutaneous anaphylaxis |
Localized anaphylaxis |
Cutaneous eruption |
Eruption |
Cyanocobalamin 25micrograms nasal spray |
Product containing only cyanocobalamin in nasal dose form (medicinal product form) |
Cyanocobalamin 500mcg nasal spray |
Cyanocobalamin 500 microgram/actuation nasal spray |
Cyanocobalamin[57Co] 370kBq/mL oral solution |
Cyanocobalamin (57-Co) only product in oral dose form |
Cyanocobalamin[58Co] 370kBq/mL oral solution |
Product containing only cyanocobalamin (58-Co) in oral dose form (medicinal product form) |
CyberKnife |
Robotic radiation delivery system |
Cyclic edema |
Edema |
Cycloanemization |
Destruction of ciliary body |
Cyclopentolate hydrochloride + phenylephrine hydrochloride |
Product containing cyclopentolate and phenylephrine (medicinal product) |
Cyclopentolate hydrochloride 0.5% conventional release eye drops |
Cyclopentolate hydrochloride 5 mg/mL eye solution |
Cyclopentolate hydrochloride 0.5% single-use eye drops |
Cyclopentolate hydrochloride 5 mg/mL eye solution |